Drug Trial Radar · NCT05133830
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Nov 23, 2021
Primary completion
May 31, 2022
Study completion May 31, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to investigate the effect of linerixibat on plasma concentrations of obeticholic acid (OCA) and its conjugates in healthy adult participants to inform the potential for drug interaction with coadministration of linerixibat and OCA.
Conditions
- Pruritus
Interventions
Obeticholic acidDrug
OCA will be administered
LinerixibatDrug
Linerixibat will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average trough concentration (Ctrough) in plasma for total-OCA at steady stateTime frame: Days 35 to 38
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.